Renovaro to Acquire Predictive Oncology in All-Stock Deal

January 6, 2025

Renovaro, an AI-powered cancer diagnostics and therapeutics company, entered into a binding LOI to acquire Predictive Oncology (POAI) in an all-stock transaction. The acquisition will allow Renovaro to combine Predictive Oncology’s large biobank and AI/ML platform with its own AI-driven liquid biopsy and cancer vaccine programs to accelerate biomarker discovery and expand clinical decision support capabilities.

Buyers
Renovaro
Targets
Predictive Oncology (POAI)
Location
United States
Transaction Type
Buyout

Explore More

Related Acquisitions

Track M&A activity that matters to you

Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.